Caujolle J-P, Maschi C, Chauvel P, Herault J, Gastaud P
Service d'ophtamolologie, CHU Saint Roch, 5 rue Pierre Devoluy, Nice Cedex 1, France.
J Fr Ophtalmol. 2009 Dec;32(10):707-14. doi: 10.1016/j.jfo.2009.10.016.
Invasive squamous cell carcinomas are uncommon neoplasias with high recurrence and mortality rates. The improvement of tumoral control requires additional treatments such as cryotherapy, topical chemotherapy, and radiotherapy. We present the technique and preliminary results of associating treatment with surgery and proton beam therapy for recurrent and invasive squamous cell carcinomas.
From June 2001 to September 2008, 15 patients were treated in our ocular oncologic center for squamous cell carcinomas either with recurrences or with invaded resection margins. The treatment combined new surgical resection with protontherapy. Specific improvements in proton beam therapy have been made at the Nice Cyclotron to adapt the treatment to conjunctival tumors. Proton beam carving consists in using a specific device to treat the thickness of the whole lesion site and the adjacent conjunctiva and to spare the surrounding healthy structures.
Patients were staged according to the TNM classification of malignant tumors in T2: 3; T3: 5; T4: 7. Mean follow-up was 39.1 months (range, 6-90 months). Our 15 patients included 12 males and three females. Left eyes were involved in eight cases. The mean age at first consultation was 63.7 years (range, 46-80 years). In 13 cases (86.8%), the bulbar and limbic conjunctiva was involved, in five of these cases the cornea was invaded, and the anterior chamber was involved in one case. In one case, the tumor was located on bulbar conjunctiva near the caruncle (6.6%) and in one case in the fornix (6.6%). One patient died of another cancer after 48 months of follow-up. We obtained local tumor control for 13 patients (86.8%) and recurrences for two patients (13.2%). One of them has presented with cervical node metastases. These two patients who presented recurring and extensive tumors had had previous repeated surgeries in other centers. Moreover, proton beam therapy was performed more than 6 months after the initial treatment. Exenteration and enucleation had to be performed to treat these recurrences 6 and 24 months after proton beam therapy. The exentered patient has been lost to follow-up. No patients developed recurrences with additional proton beam therapy performed within 6 months after initial surgical resection. As for side effects, seven patients suffered from sicca syndrome, six needed cataract surgeries, three unesthetic dilatations of episclera vessels, two conjunctival postradiation dysplasias, two experienced eyelash loss, one stenosis of the lacrimal duct, and one glaucoma controlled by monotherapy. Conjunctiva and amniotic grafts had to be performed on one of the patients presenting with dysplasia. Due to the rarity and diversity of these cases, it is nearly impossible to carry out prospective and comparative studies.
Traditional adjuvant treatments often failed to control recurring and invasive squamous cell carcinomas. We often ended up performing exenteration to control local recurrences. The preliminary results of the present study suggest that proton beam therapy may be considered as a good alternative to traditional treatments with acceptable side effects.
浸润性鳞状细胞癌是一种罕见的肿瘤,复发率和死亡率都很高。改善肿瘤控制需要额外的治疗方法,如冷冻疗法、局部化疗和放疗。我们介绍了将手术与质子束治疗相结合用于复发性和浸润性鳞状细胞癌的技术及初步结果。
2001年6月至2008年9月,15例鳞状细胞癌患者在我们的眼科肿瘤中心接受治疗,这些患者要么有复发,要么手术切缘受侵。治疗方法是将新的手术切除与质子治疗相结合。在尼斯回旋加速器对质子束治疗进行了特殊改进,以使其适用于结膜肿瘤。质子束雕刻是指使用特定设备治疗整个病变部位及其相邻结膜的厚度,并保护周围健康结构。
根据恶性肿瘤的TNM分类对患者进行分期,T2期3例;T3期5例;T4期7例。平均随访时间为39.1个月(范围6 - 90个月)。我们的15例患者中,男性12例,女性3例。左眼受累8例。首次就诊时的平均年龄为63.7岁(范围46 - 80岁)。13例(86.8%)累及球结膜和睑缘结膜,其中5例角膜受侵,1例累及前房。1例肿瘤位于泪阜附近的球结膜(6.6%),1例位于穹窿部(6.6%)。1例患者在随访48个月后死于另一种癌症。13例患者(86.8%)实现了局部肿瘤控制,2例患者(13.2%)复发。其中1例出现颈部淋巴结转移。这2例出现复发且肿瘤广泛的患者之前在其他中心接受过多次重复手术。此外,质子束治疗在初始治疗6个月后进行。在质子束治疗后6个月和24个月,不得不进行眶内容剜除术和眼球摘除术来治疗这些复发。接受眶内容剜除术的患者失访。在初次手术切除后6个月内进行额外质子束治疗的患者中,没有患者出现复发。至于副作用,7例患者患有干眼综合征,6例需要进行白内障手术,3例出现巩膜血管不美观的扩张,2例出现结膜放疗后发育异常,2例出现睫毛脱落,1例泪道狭窄,1例青光眼通过单一疗法得到控制。对1例出现发育异常的患者进行了结膜和羊膜移植。由于这些病例的罕见性和多样性,几乎不可能进行前瞻性和对比性研究。
传统辅助治疗往往无法控制复发性和浸润性鳞状细胞癌。我们常常最终进行眶内容剜除术来控制局部复发。本研究的初步结果表明,质子束治疗可被视为传统治疗的良好替代方法,且副作用可接受。